Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huJCAR014 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia
NCT03103971Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2017
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of huJCAR014 in B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia (ALL), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of toxicity up to 30 days, Dose-limiting toxicity rates up to 28 days and 4 more. Started Nov 2017; status: terminated.
02
Drugs
huJCAR014
03
Conditions
B-cell non-Hodgkin lymphomaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03103971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03103971.